English
Home > Products > CAS:427-51-0

China CAS:427-51-0 Manufacturer

"Based on domestic market and expand abroad business" is our improvement strategy for CAS:427-51-0, Now we have established steady and long business relationships with customers from North America, Western Europe, Africa, South America, more than 60 countries and regions.
CAS:427-51-0, Wide selection and fast delivery to suit your needs! Our philosophy: Good quality, great service, keep improving. We are looking forward that more and more oversea friends join in our family for further development near the future!

Related Products

Hot Products

  • Desonide

    Desonide

    Desonide has USP and EP specifications. DMF available.

    CAS:638-94-8

  • Testosterone Undecanoate

    Testosterone Undecanoate

    Testosterone undecanoate has CP specification. TP available and DMF under filing.

    CAS:5949-44-0

  • Eslicarbazepine Acetate

    Eslicarbazepine Acetate

    Eslicarbazepine Acetate has In-house specification. DMF approved.

    CAS:236395-14-5

  • Mifepristone Tablets 25mg*6

    Mifepristone Tablets 25mg*6

    Mifepristone Tablets 25mg*6
    Indications：Abortion
  • Luliconazole

    Luliconazole

    Luliconazole has In-house specification, DMF approved.

    CAS:187164-19-8

  • Abiraterone

    Abiraterone

    Abiraterone is a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), It is used in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has already spread to other parts of the body) and metastatic high-risk castration-sensitive prostate cancer.

    CAS:154229-19-3

  • Related Blog
  • Reviews

  • 2021 API Exhibition Wuhan

    October 2021
    API China is a well-established comprehensive pharmaceuticals and chemicals show in Chinese pharmaceutical industry. With more than 40 years’ experience in China, it has been a well-known celebration for all parties involved in Chinese Pharmaceutical market.

  • 2022 CPhI Exhibition Shanghai

    CPhI is the undisputed leader in the pharmaceutical industry. CPhI China offers a key access point to the second largest pharma market in the world. The exhibition features over 3,000 companies and incorporates various API showcases like bioLIVE, iCSE, NEX and FDF, creating a comprehensive platform that connects the entire pharmaceutical industry chain in the Asian-Pacific region.

  • Welcome to Xi'an API 2024

    The 91th API China & PHARMEX & PHARMPACK & SINOPHEX will be held at National Exhibition and Convention Center (Xi’an) from October 16 to 18, our booth number is 3A08.

  • What Is Epiandrosterone and Why Is It Becoming Popular in Modern Hormone Research

    In recent years, Epiandrosterone has gained increasing attention in biochemical research, pharmaceutical development, and hormone metabolism studies. As a naturally occurring androgen metabolite, this compound plays an important role in steroid biosynthesis and endocrine pathways. Scientists and manufacturers are exploring its potential applications in hormone research, biochemical analysis, and advanced pharmaceutical intermediates.

  • Why Does an APIs Category Matter So Much When Choosing a Pharmaceutical Supplier?

    When buyers search for dependable pharmaceutical raw material partners, they often focus on price, lead time, and product availability first. In my experience, that approach can overlook a more important signal: how a supplier structures its APIs Category.

  • How Can the Right Intermediates Category Simplify Pharmaceutical Sourcing?

    Selecting the right Intermediates Category is more than browsing a product list. For many buyers, it shapes sourcing speed, technical communication, documentation efficiency, batch consistency, and long-term supply confidence.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept